Hu J - Search Results

1

Drug resistance in targeted cancer therapies with RAF inhibitors.

Degirmenci U, Yap J, Sim YRM, Qin S, Hu J. Degirmenci U, et al. Among authors: hu j. Cancer Drug Resist. 2021 Jun 17;4(3):665-683. doi: 10.20517/cdr.2021.36. eCollection 2021. Cancer Drug Resist. 2021. PMID: 35582307 Free PMC article. Review.

2

The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants.

Yuan J, Ng WH, Lam PYP, Wang Y, Xia H, Yap J, Guan SP, Lee ASG, Wang M, Baccarini M, Hu J. Yuan J, et al. Among authors: hu j. Oncogene. 2018 Oct;37(43):5719-5734. doi: 10.1038/s41388-018-0365-2. Epub 2018 Jun 21. Oncogene. 2018. PMID: 29930381 Free PMC article.

3

The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF.

Yuan J, Ng WH, Yap J, Chia B, Huang X, Wang M, Hu J. Yuan J, et al. Among authors: hu j. J Biol Chem. 2018 Sep 14;293(37):14276-14284. doi: 10.1074/jbc.RA118.004597. Epub 2018 Jul 20. J Biol Chem. 2018. PMID: 30030377 Free PMC article.

4

Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis.

Yuan J, Ng WH, Tian Z, Yap J, Baccarini M, Chen Z, Hu J. Yuan J, et al. Among authors: hu j. Sci Signal. 2018 Oct 30;11(554):eaar6795. doi: 10.1126/scisignal.aar6795. Sci Signal. 2018. PMID: 30377225

5

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods.

Yap J, Yuan J, Tee ZH, Huang X, Ng WH, Hu J. Yap J, et al. Among authors: hu j. J Vis Exp. 2019 Jul 17;(149). doi: 10.3791/59795. J Vis Exp. 2019. PMID: 31380842

6

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Degirmenci U, Wang M, Hu J. Degirmenci U, et al. Among authors: hu j. Cells. 2020 Jan 13;9(1):198. doi: 10.3390/cells9010198. Cells. 2020. PMID: 31941155 Free PMC article. Review.

7

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy.

Yuan J, Dong X, Yap J, Hu J. Yuan J, et al. Among authors: hu j. J Hematol Oncol. 2020 Aug 17;13(1):113. doi: 10.1186/s13045-020-00949-4. J Hematol Oncol. 2020. PMID: 32807225 Free PMC article. Review.

8

The stability of R-spine defines RAF inhibitor resistance: A comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of αC-β4 loop.

Yap J, Deepak RNVK, Tian Z, Ng WH, Goh KC, Foo A, Tee ZH, Mohanam MP, Sim YRM, Degirmenci U, Lam P, Chen Z, Fan H, Hu J. Yap J, et al. Among authors: hu j. Sci Adv. 2021 Jun 9;7(24):eabg0390. doi: 10.1126/sciadv.abg0390. Print 2021 Jun. Sci Adv. 2021. PMID: 34108213 Free PMC article.

9

BRAF(V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes.

Yap J, Yuan J, Ng WH, Chen GB, Sim YRM, Goh KC, Teo J, Lim TYH, Goay SM, Teo JHJ, Lao Z, Lam P, Sabapathy K, Hu J. Yap J, et al. Among authors: hu j. Mol Cancer. 2023 Aug 5;22(1):125. doi: 10.1186/s12943-023-01817-8. Mol Cancer. 2023. PMID: 37543582 Free PMC article.

10

Assessment of PARP4 as a candidate breast cancer susceptibility gene.

Prawira A, Munusamy P, Yuan J, Chan CHT, Koh GL, Shuen TWH, Hu J, Yap YS, Tan MH, Ang P, Lee ASG. Prawira A, et al. Among authors: hu j. Breast Cancer Res Treat. 2019 Aug;177(1):145-153. doi: 10.1007/s10549-019-05286-w. Epub 2019 May 22. Breast Cancer Res Treat. 2019. PMID: 31119570

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

34,879 results

Search Page